107 related articles for article (PubMed ID: 35955892)
1. Phospholipase D Mediates Glutamine-Induced mTORC1 Activation to Promote Porcine Intestinal Epithelial Cell Proliferation.
Zhu M; Lu EQ; Yan L; Liu G; Huang K; Xu E; Zhang YY; Li XG
J Nutr; 2024 Apr; 154(4):1119-1129. PubMed ID: 38365119
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of CBR-5884 against epithelial ovarian cancer cells by targeting the serine synthesis pathway.
Gong K; Huang Y; Zheng Y; Zhu Y; Hao W; Shi K
Discov Oncol; 2024 May; 15(1):154. PubMed ID: 38733440
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Paclitaxel Oral Absorption and Bioavailability: TPGS Co-Coating via Supercritical Anti-Solvent Fluidized Bed Technology.
Zhong Z; Lan Y; Chen J; Ping L; Li X; Wang Q; Zhuang X; Qiu Z; Yuan T; Guo Q; Xi L; Li Q; Luo D
Pharmaceuticals (Basel); 2024 Mar; 17(4):. PubMed ID: 38675374
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment.
Fan Y; Xue H; Li Z; Huo M; Gao H; Guan X
Front Pharmacol; 2024; 15():1345522. PubMed ID: 38510646
[TBL] [Abstract][Full Text] [Related]
5. Combination of Selenite and Butyrate Enhances Efficacy Against Colon Cancer by Targeting ASCT2-Mediated Amino Acid Metabolism.
Cui J; Li J; Zhao S; Fan L; Yin S; Zhao C; Hu H
Biol Trace Elem Res; 2023 Oct; ():. PubMed ID: 37897593
[TBL] [Abstract][Full Text] [Related]
6. Metabolic control of cancer metastasis: role of amino acids at secondary organ sites.
Karno B; Edwards DN; Chen J
Oncogene; 2023 Nov; 42(47):3447-3456. PubMed ID: 37848626
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironmental nutrients, cellular responses, and cancer.
Lobel GP; Jiang Y; Simon MC
Cell Chem Biol; 2023 Sep; 30(9):1015-1032. PubMed ID: 37703882
[TBL] [Abstract][Full Text] [Related]
8. Targeting Mcl-1 Degradation by Bergenin Inhibits Tumorigenesis of Colorectal Cancer Cells.
Gan Y; Li X; Han S; Zhou L; Li W
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259388
[TBL] [Abstract][Full Text] [Related]
9. Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance.
Yue H; Lu X
Acta Biochim Biophys Sin (Shanghai); 2023 Apr; 55(6):938-947. PubMed ID: 37021977
[TBL] [Abstract][Full Text] [Related]
10. Targeting Glutaminolysis Shows Efficacy in Both Prednisolone-Sensitive and in Metabolically Rewired Prednisolone-Resistant B-Cell Childhood Acute Lymphoblastic Leukaemia Cells.
Sbirkov Y; Vergov B; Dzharov V; Schenk T; Petrie K; Sarafian V
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834787
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting.
Pejčić T; Todorović Z; Đurašević S; Popović L
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769263
[TBL] [Abstract][Full Text] [Related]
12. Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer.
Lasorsa F; di Meo NA; Rutigliano M; Ferro M; Terracciano D; Tataru OS; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674430
[TBL] [Abstract][Full Text] [Related]
13. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
Kim BR; Yoon K; Byun HJ; Seo SH; Lee SH; Rho SB
Oncotarget; 2014 Aug; 5(15):6540-51. PubMed ID: 25153728
[TBL] [Abstract][Full Text] [Related]
15. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells.
Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
17. New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic.
Yang X; Li Z; Ren H; Peng X; Fu J
Front Oncol; 2022; 12():1018642. PubMed ID: 36523985
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway.
Kim G; Jang SK; Kim YJ; Jin HO; Bae S; Hong J; Park IC; Lee JH
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955892
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
